Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis by Bogaard, E.H. van den et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/118163
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Research article
 The Journal of Clinical Investigation   http://www.jci.org 1
Coal tar induces AHR-dependent skin  
barrier repair in atopic dermatitis
Ellen H. van den Bogaard,1,2 Judith G.M. Bergboer,1 Mieke Vonk-Bergers,1  
Ivonne M.J.J. van Vlijmen-Willems,1 Stanleyson V. Hato,3 Pieter G.M. van der Valk,1  
Jens Michael Schröder,4 Irma Joosten,2 Patrick L.J.M. Zeeuwen,1 and Joost Schalkwijk1
1Department of Dermatology, Nijmegen Centre for Molecular Life Sciences, 2Laboratory of Medical Immunology, Nijmegen Institute for Infection,  
Inflammation and Immunity, and 3Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences,  
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 4Department of Dermatology,  
University Hospital of Schleswig-Holstein, Kiel, Germany.
Topical application of coal tar is one of the oldest therapies for atopic dermatitis (AD), a T helper 2 (Th2) 
lymphocyte–mediated skin disease associated with loss-of-function mutations in the skin barrier gene, filag-
grin (FLG). Despite its longstanding clinical use and efficacy, the molecular mechanism of coal tar therapy 
is unknown. Using organotypic skin models with primary keratinocytes from AD patients and controls, we 
found that coal tar activated the aryl hydrocarbon receptor (AHR), resulting in induction of epidermal dif-
ferentiation. AHR knockdown by siRNA completely abrogated this effect. Coal tar restored filaggrin expres-
sion in FLG-haploinsufficient keratinocytes to wild-type levels, and counteracted Th2 cytokine–mediated 
downregulation of skin barrier proteins. In AD patients, coal tar completely restored expression of major 
skin barrier proteins, including filaggrin. Using organotypic skin models stimulated with Th2 cytokines IL-4 
and IL-13, we found coal tar to diminish spongiosis, apoptosis, and CCL26 expression, all AD hallmarks. Coal 
tar interfered with Th2 cytokine signaling via dephosphorylation of STAT6, most likely due to AHR-regu-
lated activation of the NRF2 antioxidative stress pathway. The therapeutic effect of AHR activation herein 
described opens a new avenue to reconsider AHR as a pharmacological target and could lead to the develop-
ment of mechanism-based drugs for AD.
Introduction
Atopic dermatitis (AD) is a common inflammatory skin disease 
that has both genetic and environmental factors in its etiology. 
The pathogenesis is thought to be driven by cells of the adaptive 
immune system, mainly T helper 2 (Th2) lymphocytes. Cytokines 
derived thereof, such as IL-4, IL-5, and IL-13 contribute to disease 
symptoms in a STAT6-dependent fashion. Clinical and histopatho-
logical features include erythema, itch, loss of skin barrier func-
tion, intercellular epidermal edema (spongiosis), and keratinocyte 
apoptosis. The disease is considered to be initiated by abnormal 
exposure to external triggers (e.g., allergens) and could be due to 
an impaired skin barrier function, as exemplified by loss-of-func-
tion mutations in the filaggrin (FLG) gene (1, 2). Recent work has 
demonstrated that not only is FLG haploinsufficiency (observed in 
>25% of AD patients) or complete deficiency (as in ichthyosis vul-
garis patients) associated with AD, but the quantity of FLG repeats 
determines the risk for developing the disease as well (3). Therefore, 
upregulation of filaggrin expression in AD patients might be of 
clinical significance. Aside from the association of FLG with AD, 
other important skin barrier proteins, such as involucrin and loric-
rin, are known to be downregulated in AD by IL-4 and IL-13 via 
STAT6 signaling pathways (4). Constitutive expression of STAT6 
in mice leads to decreased expression of epidermal barrier proteins 
and subsequent development of allergic skin inflammation (5). 
Furthermore, variation in a newly discovered terminal differenti-
ation protein called hornerin, and decreased protein expression 
levels thereof, have been associated with AD (6, 7). A recent replica-
tion study, however, did not find a significant association between 
hornerin variation and AD (8). Collectively, these data underscore 
the contributions of biological interaction of skin barrier biology 
and immune mechanisms to the pathophysiology of AD.
Most of the current therapies for AD target the immune system 
(corticosteroids, calcineurin inhibitors, UVB irradiation), whereas 
emollients are used as an adjuvant to improve skin barrier func-
tion. Topical application of coal tar is an effective AD therapy for 
reducing inflammation and itch, and has been used to treat skin 
diseases for more than 2000 years. Coal tar contains over 10,000 
different organic compounds, which has precluded identification 
of its molecular mode of action, and has hampered pharmacolog-
ical investigation or drug development of its active ingredients.
Coal tar consists of a wide range of polycyclic aromatic hydrocar-
bons (PAHs) (9). Keratinocytes metabolize and detoxify internal-
ized PAHs via CYP450 enzymes, as indicated by their high levels in 
the skin of coal tar–treated individuals (10). The CYP450 enzymes 
are induced by activation of the aryl hydrocarbon receptor (AHR) 
(11). AHR is a cytoplasmic transcription factor that translocates to 
the nucleus upon ligand recognition (12), where it binds to specific 
motifs in the DNA known as xenobiotic response elements (XREs) 
(13). The recent discovery of endogenous AHR ligands revealed a 
physiological role of AHR in cell behavior and development. AHR 
was found to be crucial in regulating the development of lymphoid 
cells (14) and the induction of regulatory T cells (15, 16). Recently, 
the environmental pollutant and AHR ligand, tetrachloro-dibenzo- 
dioxin (TCDD), has been described to induce epidermal differen-
tiation, thereby providing an explanation for the occurrence of 
chloracne (17). Thus far, no endogenous AHR ligands affecting 
epidermal gene expression programs have been described.
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Using submerged cultured human keratinocytes and human 
organotypic skin models from AD patients and healthy volun-
teers, we studied the effects of coal tar exposure on the epidermal 
aspects of AD. Our results show that coal tar activates the AHR sig-
naling pathway, resulting in enhanced epidermal differentiation, 
increased levels of filaggrin, and inhibition of the IL-4/STAT6 sig-
naling pathway. These results indicate that coal tar enhances skin 
barrier function and dampens keratinocyte response to the major 
cytokines involved in AD, and point to a key role of the AHR sig-
naling pathway in the molecular mechanism by which the oldest 
known drug in dermatology corrects epidermal abnormalities in a 
common skin disease.
Results
AHR regulates coal tar–induced epidermal gene and protein expression. 
First, we investigated the potential of coal tar to activate AHR 
using cultured adult primary human keratinocytes. A coal tar 
formulation was prepared in culture medium and various con-
centrations were tested for toxicity. After 48 hours of treatment, 
none of the concentrations tested resulted in enhanced cell death 
(Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI65642DS1). In a variety of cells, 
it has been shown that upon ligand binding, AHR translocates 
to the nucleus. We indeed observed that coal tar caused AHR to 
relocate from the cytoplasm to the nucleus within 4 hours (Fig-
ure 1A), and we found a significant increase over time in the AHR 
nucleus/cytoplasm ratio upon TCDD and coal tar stimulation 
(Figure 1B). Preincubation of the antibody with recombinant 
AHR before immunofluorescence analysis completely eliminated 
nuclear staining of the coal tar–treated cells, which indicates the 
specificity of the immunofluorescence staining (Supplemental 
Figure 1B). We found a strong time- and concentration-dependent 
increase in expression of typical AHR-responsive genes such as 
CYP1A1 and CYP1B1 in coal tar–treated keratinocytes, while expres-
sion of CYP2E1 (not an AHR target) was unaffected (Figure 1C and 
Supplemental Figure 2). The response of keratinocytes to coal tar 
was similar in magnitude to their response to TCDD, a dioxin-like 
compound used as a positive control. Aside from CYP450 target 
gene expression, we also observed a highly significant and concen-
tration-dependent induction of the epidermal differentiation genes 
FLG, hornerin (HRNR), and involucrin (IVL) (Figure 1D), all pivotal 
for barrier function and all functionally related to AD (1, 2, 4, 7). 
For these genes, the induction rate achieved by high and interme-
diate coal tar concentrations was even greater than that achieved by 
TCDD. Other epidermal differentiation genes such as cystatin M/E 
(CST6), repetin (RPTN), and small proline-rich proteins 2A and 2B 
(SPRR2A and SPRR2B) were also induced after coal tar treatment, 
but to a lesser extent (Supplemental Figure 3). The induced mRNA 
expression was confirmed at the protein level by staining of coal 
tar–treated and untreated keratinocytes cultured on coverslips 
(Figure 1E) and by Western blotting (Figure 1F). Filaggrin protein 
expression in untreated keratinocytes was confined to a few multi-
layered foci, while in coal tar–treated keratinocytes, its expression 
was already present in large patches of the keratinocyte monolayer 
(Figure 1G). These results indicate that coal tar treatment induced 
filaggrin expression at early stages of keratinocyte differentiation.
To confirm the regulatory role of the AHR signaling pathway 
in the coal tar–mediated induction of epidermal differentiation 
genes, we studied the coal tar response after siRNA-mediated 
knockdown of AHR in keratinocytes. As shown in Figure 1H, a 
79% decrease in AHR expression was achieved, with a concomitant 
82% decrease in expression of its classical target gene CYP1A1. AHR 
knockdown also caused a similar decrease in coal tar–induced FLG 
and HRNR gene expression (Figure 1I) and other terminal differ-
entiation genes (Supplemental Table 1). The induction rate after 
coal tar treatment and subsequent inhibition by AHR knockdown 
was most pronounced in terminal differentiation genes with a 
reported xenobiotic response element in their promoter region 
(17), such as FLG, HRNR, and filaggrin family member 2 (FLG2). In 
contrast, the early differentiation marker keratin 10, or the basal 
keratinocyte markers keratin 5 and keratin 14, were not affected 
by coal tar stimulation or AHR knockdown. Altogether, these data 
show that coal tar induces epidermal differentiation, which is reg-
ulated by the AHR signaling pathway.
Accelerated epidermal differentiation by coal tar treatment. Next, we 
used an organotypic human skin model (hereinafter referred to 
as “skin equivalents”) to evaluate the effects of coal tar during 
epidermal morphogenesis. We have previously shown that skin 
equivalents can be used successfully to mimic many aspects of 
normal epidermis or diseased epidermis (e.g., psoriasis and AD) 
(18, 19). After 3 days of submerged culture, the skin equivalents 
were lifted at the air-liquid interface and the culture medium was 
supplemented with coal tar. Already after 4 days of culture at the 
air-liquid interface, a fully developed epidermis was observed in 
coal tar–treated skin equivalents. The untreated skin equivalents 
required 10 days of air exposure to generate a well-developed epi-
dermis (Figure 2A). From day 4 onward, the epidermis of coal tar–
treated skin equivalents continuously produced terminally differ-
entiated cells, resulting in a very thick layer of stratum corneum at 
the air-liquid interface on day 10 of culture (Figure 2A; bracket). To 
further examine the differentiation process of coal tar–treated skin 
equivalents, we analyzed protein expression at several time points 
using immunohistochemistry. Terminal differentiation markers, 
which are normally expressed from day 6 of air-exposed culture 
onward (20), were already expressed at high levels at day 4 in coal 
tar–treated skin equivalents. In particular, filaggrin, loricrin, and 
hornerin were barely present in the standard (control) cultures at 
day 4, while they were abundantly expressed in coal tar–treated 
skin equivalents (Figure 2, B and C). Therefore, we conclude that 
coal tar treatment in vitro results in accelerated epidermal differ-
entiation, and is accompanied by induced expression of terminal 
differentiation proteins.
Coal tar increases filaggrin expression in skin equivalents and in lesional 
AD skin. Based on the observed association of AD with FLG hap-
loinsufficiency and the increased risk of lower copy numbers of 
intragenic FLG repeats, it has been suggested that treatments 
resulting in increased filaggrin expression may have therapeutic 
value (3). To address this issue experimentally, we generated skin 
equivalents with keratinocytes from both healthy volunteers and 
AD patients, with a wild-type genotype or a heterozygous muta-
tion in the FLG gene, respectively (Supplemental Table 2). During 
the last 3 days of culture, we supplemented the culture medium 
with coal tar and evaluated whether coal tar would induce filag-
grin in these patient-derived skin equivalents. Filaggrin protein 
expression in skin equivalents of heterozygously mutated kera-
tinocytes was barely present in control conditions, whereas after 
coal tar treatment, filaggrin expression was evident in the granular 
layer of the epidermis (Figure 3A). As expected, wild-type keratino-
cytes responded more strongly to coal tar treatment, since they 
have 2 intact FLG alleles. Since downregulated hornerin expression 
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in AD might be important in the pathophysiology of the disease 
(7), we also evaluated hornerin protein expression and found coal 
tar–mediated upregulated hornerin expression to be similar to 
that of filaggrin (Figure 3B). To correlate our in vitro model to 
the in vivo situation, we obtained skin biopsies from AD patients 
before and during coal tar therapy. In lesional AD skin, expression 
of filaggrin and hornerin was markedly lower and discontinuous, 
or even absent, compared with normal skin, as described previ-
ously (7). Already after 3 days of coal tar treatment, expression of 
these proteins was strongly induced in lesional AD skin, and after 
7 days of coal tar therapy, a continuous expression pattern was 
observed (Figure 3C), resembling that of normal skin. We also ana-
lyzed other epidermal differentiation proteins and found strongly 
upregulated expression of loricrin and involucrin proteins both 
Figure 1
Coal tar induces epidermal differentiation via AHR signaling. (A) AHR staining of coal tar–treated or untreated keratinocytes. Nuclei were counter-
stained using DAPI. Scale bar: 100 μM. (B) Semiquantitative analysis of nuclear and cytoplasmic fluorescence intensity (FI) measured by ImageJ 
software. *P < 0.05, **P < 0.01, and ***P < 0.001, relative to untreated keratinocytes. Bars indicate mean ± SEM (n = 3). (C) CYP450 mRNA 
expression levels after 48 hours of stimulation with TCDD or a coal tar concentration series. Expression levels are relative to untreated (control) 
keratinocytes. *P < 0.05 and **P < 0.001. Bars indicate mean ± SEM (n = 3). (D) mRNA expression levels of epidermal differentiation genes after 
48 hours of stimulation with TCDD or a coal tar concentration series. Expression levels are relative to untreated (control) keratinocytes. Bars indi-
cate mean ± SEM (n = 3). (E) Filaggrin and hornerin staining of 2% coal tar–treated or untreated keratinocytes. Nuclei were counterstained using 
DAPI. Scale bar: 100 μM. (F) Western blot analysis of filaggrin protein in lysates of coal tar–treated and untreated keratinocytes from 2 keratinocyte 
donors. (G) Filaggrin staining of 2% coal tar–treated or untreated keratinocytes. Nuclei were counterstained using hematoxylin. Scale bar: 100 
μM. (H) AHR and CYP1A1, and (I) FLG and HRNR mRNA expression levels after siRNA-mediated AHR knockdown and subsequent 2% coal tar 
stimulation. Expression levels are relative to mock-treated, coal tar–stimulated keratinocytes. Bars indicate mean ± SEM (n = 3).
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in vitro and in vivo (Figure 3D), suggesting that AD patients may 
benefit from enhanced epidermal differentiation in general, as well 
as improved barrier function.
Coal tar normalizes histopathological and molecular hallmarks of AD in 
skin equivalents. Th2 cytokines like IL-4 and IL-13 induce spongiosis 
and apoptosis in skin equivalents, probably via STAT6 signaling 
(18). These cytokines were also shown to downregulate involucrin 
and loricrin expression via STAT6 (4). Furthermore, the constitu-
tive expression of STAT6 in transgenic mice has been demonstrated 
to lead to an increased risk of developing AD (5). We therefore stim-
ulated skin equivalents with IL-4 and IL-13 to induce an AD phe-
notype in vitro as previously described (18), and tested the effect of 
coal tar. We found that coal tar treatment prevented the occurrence 
of spongiosis and apoptosis and could “cure” these symptoms in 
a therapeutic experimental design; both simultaneous addition of 
Th2 cytokines and coal tar, and coal tar treatment after Th2 stim-
ulation, resulted in improvement of the phenotype (Figure 4, A 
and B). Although Th2 cytokine–mediated apoptosis was reported 
to be associated with increased expression of FAS (21), we did not 
observe downregulated FAS levels after coal tar treatment (Figure 
4C). In our skin equivalent model, we confirmed the reported Th2 
cytokine–mediated downregulation of epidermal differentiation 
proteins (4) and found coal tar treatment to restore both mRNA 
(Figure 4D) and protein expression (Figure 4, E and F). This was 
also confirmed in coal tar–treated AD patients in vivo (Figure 3D). 
Eosinophilia has been associated with AD, and the degree of eos-
inophilia correlates with AD severity (22). CCL26, or eotaxin-3, a 
chemokine for eosinophils, is upregulated in keratinocytes by IL-4 
via the STAT6 signaling pathway (23). Our results have shown coal 
tar to diminish the downstream effects of IL-4, therefore we ana-
lyzed CCL26 levels in our AD skin equivalent model after coal tar 
treatment. The highly upregulated CCL26 expression levels in skin 
equivalents after Th2 cytokine stimulation were completely nor-
malized after coal tar treatment (Figure 4G), indicating that coal 
tar directly targets the innate immune system by interfering with 
the keratinocyte response following Th2 cytokine stimulation.
Coal tar interferes with the Th2 cytokine–mediated STAT6 signaling 
cascade. Since most of the aforementioned effects of Th2 cytokine 
stimulation in keratinocytes act via STAT6 signaling, we hypoth-
esized that coal tar interferes with this signaling cascade. Both 
phosphorylated STAT6 (pSTAT6) and total STAT6 levels were 
determined using Western blot analysis, which revealed that stim-
ulation with IL-4 and IL-13 induced STAT6 phosphorylation 
in keratinocytes (Figure 5A). Thereafter, we supplemented Th2 
cytokine–stimulated keratinocytes with coal tar for 6 hours and 
observed markedly reduced pSTAT6 levels in these cell lysates 
(Figure 5A). pSTAT6 is a known substrate for protein tyrosine 
phosphatase 1B (PTPN1) (24). In addition, oxidative stress 
induced by Th2 cytokine stimulation in keratinocytes results in 
oxidative inactivation of PTPN1, and thus sustained STAT6 phos-
phorylation (25). We therefore hypothesized that the molecular 
mechanism of coal tar–mediated inhibition of STAT6 phosphory-
lation could, at least in part, act via inhibition of the oxidative inac-
tivation of PTPN1. AHR is known as a sensor of the redox system 
against oxidative stress and regulates nuclear factor erythroid 2– 
related factor 2 (NRF2), a master switch of the redox machinery 
(26). We found coal tar to induce both nuclear translocation of 
NRF2 (Figure 5B) and subsequent induction of its target gene, 
Figure 2
Accelerated epidermal differentiation by coal tar. (A) H&E 
staining of human skin equivalents cultured in the presence 
or absence (control) of coal tar during the entire air-liquid 
interface culture. Bracket indicates the thickness of the stra-
tum corneum. (B) Immunohistochemical staining of filag-
grin, loricrin, and hornerin in skin equivalents at day 4 of the 
air-liquid interface culture when cultured in the presence or 
absence (control) of coal tar. Images are representative of 
3 keratinocyte donors, and the experiment was replicated 
twice. Scale bar: 100 μM. (C) Filaggrin and loricrin Western 
blotting of skin equivalents harvested on day 4 or day 10 
of air-liquid interface culture, treated with or without coal tar 
during the entire culture period.
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NAD(P)H quinone oxidoreductase 1 (NQO1) in keratinocytes 
(Figure 5C). Remarkably, no induction of NQO1 was observed in 
keratinocytes following TCDD exposure. Upon AHR knockdown, 
induction of NQO1 expression was inhibited, indicating the regu-
latory role of AHR in NRF2-mediated signaling in keratinocytes 
(Figure 5D). Our data indicate that coal tar activates the antiox-
idative stress pathway via NRF2 signaling, which might inhibit 
Th2-induced oxidative stress and result in STAT6 dephosphory-
lation and abrogation of the inflammatory Th2-mediated STAT6 
signaling cascade in keratinocytes (Figure 6).
Discussion
AD is a highly prevalent inflammatory skin disease caused by 
skin barrier dysfunction and chronic immune activation (27, 28). 
Figure 3
Restored filaggrin and hornerin protein expression by coal tar. Skin equivalents generated from keratinocytes from AD patients harbor-
ing a heterozygous FLG mutation (FLG–/+; n = 3) and healthy control wild-type (WT; n = 3) keratinocytes were treated with coal tar during 
the last 3 days of air-liquid interface culture. Skin equivalents were stained for (A) filaggrin, and (B) hornerin protein expression analysis. 
(C) Immunohistochemical analysis of filaggrin and hornerin protein expression in skin biopsies from AD patients receiving coal tar therapy 
(n = 3). Scale bar: 100 μM. (D) Immunohistochemical analysis of loricrin and involucrin protein expression in skin biopsies from AD patients 
receiving coal tar therapy (n = 3). Scale bar: 100 μM.
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No mechanism-based therapies are available for AD patients and 
treatment is mainly focused on symptom relief, predominantly 
targeting dry skin, itch, and inflammation with emollients and 
corticosteroids. Since the seminal work of the McLean Lab has 
underscored the importance of skin barrier abnormalities as an 
etiological factor in AD, we focused on the effects of coal tar on 
the epidermal biology of this disease (1, 3, 8). Our results reveal 
a key role of the AHR signaling pathway in breaching the vicious 
Figure 4
Coal tar attenuates Th2 cytokine–induced AD hallmarks. (A) H&E staining of skin equivalents stimulated with Th2 cytokines for 3 days, or treated 
with coal tar thereafter (Th2 → coal tar), or simultaneously stimulated with Th2 cytokines and coal tar (Th2 + coal tar). Closed arrowheads 
indicate spongiosis. Images are representative of 3 keratinocyte donors. The experiment was replicated twice. Scale bar: 100 μM. (B) TUNEL 
assay on matching skin equivalents as depicted in A, showing apoptotic cells indicated by open arrowheads. Scale bar: 100 μM. (C) FAS mRNA 
expression levels in skin equivalents after Th2 cytokine stimulation and coal tar treatment. Expression levels are relative to untreated (control) 
keratinocytes. Bars indicate mean ± SEM (n = 3). (D) mRNA expression levels of epidermal differentiation genes after Th2 cytokine stimulation 
and coal tar treatment. Expression levels are relative to untreated (control) keratinocytes. Bars indicate mean ± SEM (n = 3). *P < 0.05 and 
**P < 0.01. (E) Immunohistochemical staining of loricrin and involucrin in skin equivalents stimulated with Th2 cytokines for 3 days, or treated 
with coal tar thereafter (Th2 → coal tar). Images are representative of 3 keratinocyte donors. The experiment was replicated twice. Scale bar: 
100 μM. (F) Loricrin, involucrin, and filaggrin Western blotting of skin equivalents are depicted in E. (G) CCL26 mRNA expression levels after Th2 
cytokine stimulation and coal tar treatment by qPCR analysis. Expression levels are relative to untreated (control) keratinocytes. Bars indicate 
mean ± SEM (n = 3). ***P < 0.001.
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circle of chronic inflammation by improving skin barrier func-
tion and interfering with Th2 cytokine signaling and down-
stream pathological processes.
The immunopathogenesis of AD has been studied directly on 
patients or in animal models based on allergic immune responses 
(29–31). We have recently developed in vitro organotypic mod-
els for psoriasis and AD (18, 19), and have shown that the appli-
cation of genetic techniques in these models could be used to 
study epidermal aspects of diseases (32). Others showed that FLG 
knockdown in human skin equivalents could mimic AD skin by 
impaired epidermal differentiation and barrier dysfunction (33, 
34). We have chosen keratinocyte-only human skin equivalents to 
evaluate the effect of coal tar on the epidermis, thereby excluding 
the possible effects of coal tar and subsequent AHR activation on 
other skin cell types such as fibroblasts and immune cells, as these 
cells could in turn affect epidermal processes. Genetic approaches 
to modify keratinocyte gene expression were introduced in this 
system by using an siRNA knockdown approach to prove the 
role of AHR, or by using patient-derived keratinocytes harboring 
one FLG-null allele. These findings illustrate the power of skin 
equivalents to study human skin diseases and, to a certain extent, 
to replace mouse models.
In the early seventies, attempts were made to unravel the mech-
anism of action of coal tar therapy. Suppression of DNA synthe-
sis (35, 36) and induction of a granular layer using the mouse 
tail test (37, 38) have been reported. The mouse tail test has pre-
viously demonstrated the effects of coal tar on epidermal differ-
entiation. Since the discovery of FLG mutations in AD, it is now 
widely accepted that epidermal barrier dysfunction is key in the 
pathophysiology of this disease. These new insights are strongly 
guiding current efforts in AD research and therapy development. 
The accelerated filaggrin expression and barrier function in fetal 
mouse skin due to dioxin-mediated AHR activation (17, 39) sug-
gested to us that there is a potential role for AHR in AD treat-
ment. Here, we show that coal tar activates AHR signaling and 
found that AHR regulates and induces epidermal differentiation 
and stimulates filaggrin expression in keratinocytes harboring 
a monoallelic FLG loss-of-function mutation. These findings 
may have a major impact on the reappraisal of coal tar therapy, 
which is gradually being abandoned by dermatologists due to its 
cosmetic side effects, safety concerns, and a hitherto unknown 
mechanism of action.
The AHR signaling pathway is currently of great interest. 
Though it was previously only considered to be related to immu-
notoxicity, recent findings have underscored this pathway’s 
physiological role. AHR appears to be predominantly involved 
in the development and function of the immune system (14, 
40–43). Genetic approaches in mice, however, have also revealed 
that AHR signaling plays a role in epidermal pathophysiology. 
Deficiency or constitutive expression of AHR interaction part-
ners ARNT (44, 45) and NRF2 (46), respectively, has detrimen-
tal effects on epidermal differentiation and barrier function, 
whereas AHR transgenic mice develop inflammatory skin lesions 
with hyperkeratinization (47). All these studies show that distur-
bance of normal AHR signaling, either by genetic approaches or 
TCDD exposure, leads to epidermal abnormalities. Our study is 
the first to demonstrate the beneficial therapeutic effects of AHR 
activation on epidermal differentiation and barrier function in 
a skin disease characterized by low levels of terminal differen-
tiation proteins and the resultant poor barrier function. The 
Figure 5
STAT6 dephosphorylation and NRF2 activa-
tion by coal tar. (A) Western blot analysis of 
phosphorylated STAT6 (pSTAT6) and total STAT6 
levels in lysates of 2 keratinocyte donors. Kera-
tinocytes were stimulated for 12 hours with dif-
ferentiation medium (–/–), Th2 cytokines (+/–), or 
2% coal tar (–/+), and with Th2 cytokines during 
the first 6 hours, followed by the addition of 2% 
coal tar and stimulation for another 6 hours (+/+). 
Thin black line indicates that the lanes were run 
on the same gel, but were noncontiguous. (B) 
Immunofluorescence staining of NRF2 in coal 
tar–treated or untreated keratinocytes. Nuclei were 
counterstained using DAPI. Images are represen-
tative of 3 keratinocyte donors. Original magnifica-
tion, ×400. (C) qPCR analysis of NRF2 and NQO1 
mRNA expression levels in keratinocytes. Expres-
sion levels are relative to untreated (control) kera-
tinocytes. *P = 0.002 relative to control condition. 
Bars indicate mean ± SEM (n = 3). qPCR analysis 
of mRNA expression levels of AHR (D) and NQO1 
(E) after siRNA-mediated AHR knockdown and 
subsequent coal tar stimulation by qPCR analy-
sis. Expression levels are relative to mock-treated, 
coal tar–stimulated keratinocytes. *P = 0.006 and 
**P = 0.032, relative to mock-treated keratinocytes. 
Bars indicate mean ± SEM (n = 3).
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therapeutic use of AHR ligands appears controversial in light 
of the complete ban on all AHR ligands instituted by the phar-
maceutical industry because of the widely known dioxin-related 
toxic effects of AHR activation. However, recent interest in the 
AHR signaling pathway has led to a variety of reports describing 
diverse downstream effects by different exogenous and endoge-
nous AHR agonists. Nowadays, therefore, it is recognized that 
the specific ligand-receptor interaction determines the down-
stream effects of AHR activation, and that it is not merely a mat-
ter of drug potency. Hence, CYP1A1 induction and/or AHR acti-
vation are not synonymous with dioxin-like toxicity.
In addition to the improved epidermal differentiation and filag-
grin induction by coal tar–mediated AHR activation, we made the 
exciting observation that coal tar normalizes histopathological 
and molecular hallmarks of AD, and found STAT6 to be the key 
player in this process in keratinocytes. Although we were unable 
to directly measure the putative phosphatase (PTPN1) activity 
responsible for inactivating STAT6 activity (24) in keratinocytes, 
we do provide evidence that both upstream (NRF2) and down-
stream (STAT6) pathways are affected by coal tar. Therefore, it is 
very likely that coal tar inhibits oxidative inactivation of PTPN1, 
and thereby attenuates STAT6 activation. The Th2 immune 
response, as observed in atopic diseases like AD, is also driven by 
STAT6 via IL-4–induced maturation and development of Th2 cells 
(48, 49). Based on our data, we believe that AHR has great poten-
tial as a pharmacological target in atopic or allergic diseases, espe-
cially because it was recently shown that the AHR agonist FICZ 
(a tryptophan metabolite) suppresses eosinophilia, Th2 cytokine 
production, and STAT6 activation in allergic asthma in mice (50). 
Moreover, PTPN1 deficiency results in exacerbated 
lung inflammation in mice due to early recruitment 
of leukocytes and elevated levels of lung CCL26 and 
Th2 cytokine levels (51). Since coal tar metabolites 
are found in urine of patients receiving coal tar ther-
apy (52), suggesting the systemic entrance of coal tar 
components following topical application, the thera-
peutic success of coal tar therapy may, in addition to 
its epidermal effects, also rely on suppression of the 
immune response by dampening STAT6 activation 
in immune cells. The reported role of AHR in Treg 
development is likely to contribute to the therapeutic 
efficacy of coal tar in two major skin diseases: psori-
asis and AD. The scope of our current investigations, 
however, was limited to epidermal aspects of AD and 
the effect of coal tar.
In addition to the recently uncovered role of NRF2 
in epidermal barrier function, its main function lies 
in the defense against oxidative stress, and it is there-
fore proposed as a potential pharmacological target 
for chemoprevention (53). NRF2 has been linked to 
the AHR signaling pathway mostly in mice liver tissue 
after dioxin exposure (54). Here we show that coal tar, 
but not TCDD, induces NRF2 activation and subse-
quent expression of NQO1 in human keratinocytes. 
Upon knockdown of AHR, significantly less NQO1 
was expressed, indicating an interaction between 
AHR and NRF2 in human keratinocytes. The discrep-
ancy between the previously reported TCDD-induced 
NQO1 levels and the lack of such induction in kera-
tinocytes is in itself not unprecedented, and may be 
explained by species and cell type differences and ligand-specific 
effects (55). Therefore, the induction of a protective mechanism 
(NQO1 induction) in keratinocytes after coal tar exposure might 
explain the lack of toxicity and carcinogenicity associated with 
the medicinal use of coal tar (56), while AHR activation by TCDD 
leads to severe symptoms such as chloracne and immunotoxicity, 
as well as an increased risk of cancer.
Although coal tar therapy is the oldest known dermatological 
treatment, questions still remain regarding its safety and possible 
carcinogenicity (57). A comprehensive study by Roelofzen et al. in 
2010 (56) did not find a relation between an increased risk of skin 
or non-skin malignancies and coal tar therapy in a large cohort of 
13,200 psoriasis and eczema patients. AHR ligands are currently 
excluded from drug discovery and development pipelines due to 
the exposure-related toxicity and carcinogenicity of some of its 
known ligands, such as dioxin and benzo[a]pyrene. The emerging 
evidence of a more physiological role of AHR, and the therapeutic 
effect of AHR activation herein described, suggest that it might 
be the right time to reconsider whether it is justifiable to exclude 
AHR as a pharmacological target.
Methods
Coal tar formulations. Pix Licantrix (medicinal coal tar) obtained from BUFA 
(Spruyt Hillen) was added to keratinocyte differentiation medium supple-
mented with 0.5 mg/ml delipidized BSA at an initial concentration of 2% 
(v/v). After overnight vortexing at room temperature, the saturated coal tar 
suspension was centrifuged and the supernatant was sterilized by 0.2 μm 
filtration. This solution was diluted 10 times in culture medium to obtain 
the highest nontoxic concentration (this condition was further designated 
Figure 6
Model of the molecular mechanism of coal tar therapy in AD. Th2 cytokines 
IL-4 and IL-13 activate the STAT6 signaling cascade, leading to downregulated 
expression of epidermal differentiation proteins, induction of the eosinophilic 
chemoattractant CCL26, and histopathological features such as spongiosis and 
apoptosis. Under normal conditions, PTPN1 dephosphorylates STAT6, resulting 
in a regulatory feedback loop. However, oxidative stress caused by Th2 cytokines 
inactivates PTPN1, leading to sustained STAT6 signaling. Coal tar–mediated acti-
vation of the AHR signaling pathway leads to enhanced epidermal differentia-
tion and possible improvement of epidermal barrier function, thereby attenuating 
allergen exposure and reducing inflammatory cues. Importantly, coal tar activates 
the AHR/NRF2 signaling pathway, enabling detoxification of reactive oxygen spe-
cies. This may prevent the oxidative inactivation of PTPN1 and lead to decreased 
STAT6 signaling, normalization of skin barrier protein expression, and downreg-
ulation of CCL26 expression.
Downloaded from http://www.jci.org on February  3, 2016.   http://dx.doi.org/10.1172/JCI65642
research article
 The Journal of Clinical Investigation   http://www.jci.org 9
another 24 hours. Keratinocytes were thereafter allowed to differentiate 
for 48 hours in the presence of coal tar. Cells were harvested for transcrip-
tional analysis as described above.
Clinical studies. Three AD patients hospitalized to receive coal tar treat-
ment in our medical center were included in the study. Coal tar treatment 
consisted of the application of 5% crude coal tar ointment (pix lithantracis 
in zinc oxide paste) to the affected body area twice daily. Three-millime-
ter biopsies were taken under local anesthesia from lesional skin prior to 
treatment and on days 3 and 7 of treatment. Biopsies were taken from the 
center of active lesions, avoiding blisters or wounds.
FLG mutation analysis. Genomic DNA was extracted from saliva samples 
using the Oragene kit (DNA Genotek Inc.) according to the manufactur-
er’s protocol. For analysis of the p.R501X (c.1501C>T) and c.2282del4 
mutations, we used the previously published primers FilH1F3/RPT1P6 
and RPT1P7/RPT2P1, respectively (62). DNA (50 ng) was diluted in PCR 
reaction buffer containing 1.6 mM MgCl2 and Platinum Taq Polymerase 
(Invitrogen; Life Technologies). PCR conditions were as follows: 94°C for 
5 minutes; 35 cycles of 94°C for 30 seconds; 58°C for 45 seconds; 72°C 
for 75 seconds; and the final extension step at 72°C for 7 minutes. The 
amplified PCR products were resolved on a 1.5% agarose gel, purified by 
using the NucleoSpin Gel and PCR Clean-up kit (BIOKÉ), and sequenced 
using dye termination chemistry on a 3730 DNA analyzer (Applied Bio-
systems; Life Technologies).
Western blot analysis. Keratinocytes or epidermal sheets from skin equiva-
lents separated by dispase treatment were lysed in RIPA lysis buffer. After 
a single cycle of freeze-thawing, the lysates were centrifuged at maximum 
speed for 10 minutes at 4°C. The supernatant was used for involucrin 
immunoblotting. Total protein concentration of the supernatant was 
determined, and a total of 12.5 μg protein was loaded for each sample. 
The pellet containing the insoluble fraction was resuspended in sample 
buffer, sonicated, and boiled for 5 minutes and used for filaggrin and loric-
rin detection. For submerged cultured keratinocyte lysates, actin antibody 
(Sigma-Aldrich) was used to control equal protein loading. To control 
equal loading of the insoluble fraction from skin equivalent epidermis, 
Coomassie Blue staining of gels and Poncea–u S staining of blots were 
used (data not shown). Prior to immunoblotting, proteins were separated 
by SDS page and transferred to PVDF membranes using the NuPAGE sys-
tem (Life Technologies). LumiGLO (Cell Signaling Technology Inc.) was 
used for chemiluminescent detection by the Bio-Rad Universal Hood Gel 
Imager (Bio-Rad Laboratories).
STAT6 phosphorylation was analyzed in primary human keratinocytes 
after IL-4 and IL-13 stimulation as described previously (18), with coal tar 
supplemented in the culture medium at indicated time points.
Statistics. Data are given as mean ± SEM of at least 3 biological repli-
cates. Statistical analysis of quantitative PCR (qPCR) data was performed 
on ΔCt values using commercially available software (PASW Statistics 18; 
SPSS Inc.). One-way analysis of variance, followed by Bonferroni post hoc 
testing and 2-tailed, paired t tests were performed. P < 0.05 was consid-
ered statistically significant.
Study approval. The study was approved by the local medical ethical com-
mittee and was conducted according to Declaration of Helsinki principles. 
Informed consent was obtained from all patients and healthy volunteers.
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as the “2%” concentration in all experiments). Further dilutions in culture 
medium were made from this solution. Coal tar is known to be composed 
of a large number (>10,000) of organic compounds, many of which are 
nonpolar and practically insoluble in aqueous solution. The presence of 
delipidized BSA in the medium is likely to have facilitated the solubility 
of part of the nonpolar fraction, but no attempt was made to quantify the 
fraction of the crude coal tar that was actually dissolved.
Toxicity testing. Cellular toxicity was measured using cell supernatant and 
lactate dehydrogenase analysis according to the manufacturer’s recom-
mendations (Roche). Percentage of cell death, which was set at 100%, was 
relative to 1% Triton-X/PBS–treated keratinocytes.
Submerged keratinocyte culture. Keratinocytes were isolated from human 
abdominal skin derived from donors who underwent surgery for abdom-
inal wall correction, as previously described (17). For submerged culture, 
keratinocytes were cultured in keratinocyte growth medium (Lonza) and 
differentiated by depletion of growth factors, as described previously (58). 
Coal tar was supplemented during the differentiation phase at indicated 
concentrations. The study was conducted in accordance with Declaration 
of Helsinki principles. 
Skin equivalent development. Human skin equivalents were generated 
using de-epidermized dermis, as described previously, and seeded with 105 
human primary keratinocytes (17). Skin equivalents were cultured sub-
merged for 3 days, after which the medium level was decreased and equiv-
alents were cultured at the air-liquid interface at indicated time points in 
the presence of coal tar.
Skin morphology. Six-micrometer sections were obtained from paraf-
fin-embedded, formalin-fixed skin equivalents or skin biopsies and were 
stained with H&E.
Indirect immunostaining of skin equivalents or biopsies and keratinocyte cul-
tures. Indirect immunoperoxidase technique with avidin-biotin complex 
enhancement (Vectastain; Vector Laboratories) was used to analyze epi-
dermal differentiation. The following antibodies were used: antibodies 
against filaggrin (1:6000; Biomedical Technologies Inc.); loricrin (1:500; 
BabCO); involucrin (1:50; Mon150; generated by our lab, van Duijnhoven 
[1992], University of Geneva, Switzerland); and hornerin (antibody was 
raised against full-length recombinant HRNR repeat domains, 1:200; 
ref. 59). For translocation of AHR and NRF2 (1:200, Santa Cruz), direct 
immunofluorescence labeling was performed using Alexa Fluor 488 conju-
gate in conjunction with fluorescence microscopy, and fluorescence inten-
sity of nuclei and cytoplasm was measured by ImageJ software. The average 
mean FI nucleus/cytoplasm ratio of 10 cells per experimental condition 
was calculated from 3 keratinocyte donors. Preincubation of 2 μg AHR 
human recombinant protein (Abnova) with a 1:200 dilution of AHR anti-
body for 1 hour at room temperature was performed prior to incubation 
with the cell cultures to determine antibody specificity.
Transcriptional analysis. Epidermis was separated from the skin equiva-
lents by dispase treatment (Roche) for 2 hours at 4°C. Total RNA from 
epidermis and cultured keratinocytes were isolated using Trizol reagent 
(Life Technologies) and a microprep kit (QIAGEN). Dnase I–treated 
(Invitrogen; Life Technologies) and reverse transcription PCR products 
were analyzed using the MyiQ Single-Color Real-Time Detection System 
for quantification with SYBR Green and melting curve analysis (Bio-Rad 
Laboratories). Expression of target genes was normalized to expression 
of the housekeeping gene human ribosomal phosphoprotein P0 (RPLP0) 
in the same sample (60). Relative mRNA expression levels were calculated 
using the ΔΔCt method (61).
siRNA knockdown. Keratinocytes were grown to 60% confluency, and 
500 nM of smartpool AHR targeting or nontargeting siRNA (Accell 
Dharmacon; Thermo Scientific) was added for 48 hours. Culture 
medium was subsequently refreshed and supplemented with siRNA for 
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